Characterization of Serum Proteins Associated with IL28B Genotype among Patients with Chronic Hepatitis C by Cyr, Derek D. et al.
Characterization of Serum Proteins Associated with
IL28B Genotype among Patients with Chronic Hepatitis C
Derek D. Cyr
1, Joseph E. Lucas
1, J. Will Thompson
1, Keyur Patel
2, Paul J. Clark
2, Alexander Thompson
2,
Hans L. Tillmann
2, John G. McHutchison
2, M. Arthur Moseley
1, Jeanette J. McCarthy
1,3*
1Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America, 2Duke Clinical Research Institute and the
Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina, United States of America, 3Division of Community and Family Medicine, Duke
University Medical Center, Durham, North Carolina, United States of America
Abstract
Introduction: Polymorphisms near the IL28B gene (e.g. rs12979860) encoding interferon l3 have recently been associated
with both spontaneous clearance and treatment response to pegIFN/RBV in chronic hepatitis C (CHC) patients. The
molecular consequences of this genetic variation are unknown. To gain further insight into IL28B function we assessed the
association of rs12979860 with expression of protein quantitative traits (pQTL analysis) generated using open-platform
proteomics in serum from patients.
Methods: 41 patients with genotype 1 chronic hepatitis C infection from the Duke Liver Clinic were genotyped for
rs12979860. Proteomic profiles were generated by LC-MS/MS analysis following immunodepletion of serum with MARS14
columns and trypsin-digestion. Next, a latent factor model was used to classify peptides into metaproteins based on co-
expression and using only those peptides with protein identifications. Metaproteins were then analyzed for association with
IL28B genotype using one-way analysis of variance.
Results: There were a total of 4,186 peptides in the data set with positive identifications. These were matched with 253
proteins of which 110 had two or more associated, identified peptides. The IL28B treatment response genotype
(rs12979860_CC) was significantly associated with lower serum levels of corticosteroid binding globulin (CBG; p=9.2610
26),
a major transport protein for glucocorticoids and progestins. Moreover, the CBG metaprotein was associated with treatment
response (p=0.0148), but this association was attenuated when both IL28B genotype and CBG were included in the model,
suggesting that the CBG association may be independent of treatment response.
Conclusions: In this cohort of chronic hepatitis C patients, IL28B polymorphism was associated with serum levels of
corticosteroid binding globulin, a major transporter of cortisol, however, CBG does not appear to mediate the association of
IL28B with treatment response. Further investigation of this pathway is warranted to determine if it plays a role in other
comorbidities of HCV-infection.
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Introduction
Hepatitis C virus (HCV) infecton is a global health concern with
an estimated prevalence of up to 170 million people infected
worldwide [1]. Complications from liver disease as a consequence
of chronic hepatitis C (CHC) infection is the leading cause for liver
transplantation in the United States [2]. Response to current
standard of care interferon-based treatment regimens is effective in
less than one-half of infected individuals. Recently, polymorphisms
in the vicinity of the IL28B gene, encoding interferon l3, have
been associated with both spontaneous clearance and virologic
response to pegylated interferon-alpha and Ribavirin therapy
(pegIFN/RBV) among patients with CHC [3–7]. The underlying
functional genetic variant(s) responsible for this observed associ-
ation remains to be identified, yet several SNPs, including
rs12979860, appear to be robust markers of its effect.
CHC patients who respond to pegIFN/RBV tend to have lower
pre-treatment expression levels of interferon stimulated genes
(ISGs) in the liver [8]. Honda and colleagues carried out
expression quantitative trait locus (eQTL) analysis, examining
the IL28B SNP association with liver gene expression levels of
ISGs and found that hepatic ISGs were significantly lower in HCV
patients with the IL28B ‘responder’ genotype compared to patients
without this genotype [9]. These results were independently
replicated in another study [10], supporting the idea that a lower
endogenous interferon response increases the likelihood of
treatment response. However, little else is known about the
mechanism through which IL28B influences viral clearance.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21854We recently assessed a cohort of CHC patients and reported a
proteomic signature of HCV treatment response measured in pre-
treatment serum samples that was highly predictive of response to
peg-interferon/Ribavirin [11], with equivalent performance to
IL28B genotype. Interestingly, the proteomic signature and IL28B
genotype demonstrated only partial correlation, suggesting unique
pathways to predict response. Serum proteomic data from that
investigation were utilized in the current study to explore the
correlation of genetic variation with downstream protein expres-
sion. This protein quantitative trait locus (pQTL) analysis builds
on the success of eQTL analysis, where correlation of genetic
variation with downstream mRNA expression has provided
insights into the functional consequence of genetic variation. Prior
studies employing similar methods have demonstrated the
effectiveness of such an approach for identifying genetic variants
controlling protein expression in yeast [12]. In humans, large-scale
pQTL analysis of proteins measured by standard laboratory assays
have also been performed [13]. Both studies confirm the utility of
identifying both cis-acting (located close to the gene encoding the
protein) and trans-acting (located elsewhere in the genome) loci. In
the current study we use an unbiased, label-free proteomic
platform to characterize serum proteins associated with an IL28B
polymorphism that has been strongly associated with HCV
clearance.
Results
The study included 41 genotype 1 CHC patients that were
predominantly Caucasian (78%), male (61%), treatment respond-
ers (63%) with moderate to advanced fibrosis (85%) and a mean
age of 47.4 years. The favorable response IL28B CC genotype was
observed in close to one-half of our cohort. Table 1 summarizes
this patient cohort.
Metaproteins associated with IL28B genotype
There were a total of 4,186 peptides in the data set with
identifications by MS/MS at a 1% false discovery rate. Latent
factor modeling grouped the individual peptides into 110
metaproteins. P-values generated from the association analysis of
each of the 110 metaproteins and rs12979860 genotype are shown
in the quantile-quantile (QQ) plot in Figure 1. A single
metaprotein showed significant association with IL28B genotype
after Bonferroni correction for multiple hypothesis testing: the liver
protein corticosteroid binding globulin (CBG; p=9.2610
26). The
rs12979860 ‘C’ (responder) allele was associated with lower levels
of CBG metaprotein and explained 46% of the variance in CBG
metaprotein (Figure 2). These results remained significant when
testing a recessive model (CC versus TC/TT; p=7.45610
25).
If the previously reported association between IL28B and SVR
is mediated through CBG, we would expect to see an association
between CBG and SVR in this cohort as well. Indeed, we found a
statistically significant association between the CBG metaprotein
expression and SVR (p=0.0148). We also found a statistically
significant association (p=0.0021) between the IL28B genotype
and SVR, as reported previously in patients from the Duke
Hepatology Clinic cohort [14]. However, when including both
IL28B genotype and CBG in a model to predict SVR, the
association with CBG was completely attenuated (p=0.46) while
the IL28B association remained significant (p=0.0145), suggesting
that CBG is probably not mediating the association between
IL28B and SVR. These results are summarized in Table 2.
The CBG metaprotein included all (5 of 5) of the CBG peptides
generated, as well as individual peptides from three other proteins
(Figure 3). As expected, the correlation between all five of the CBG
peptides is high (0.84,r,0.95) and correlations between CBG
peptides and the AFAM, HEMO and APOB peptides are also
high (0.57,r,0.94). Each of these component peptides was tested
for association with IL28B genotype to determine whether all or
only some of the peptides contributed to the association observed
with the metaprotein (Table 3). All eight component peptides were
found to be statistically significant, even with correction for
multiple hypotheses (p#0.006).
Discussion
We recently reported the successful application of an unbiased
LC-MS/MS platform for proteomic expression signatures associ-
ated with HCV treatment response [11]. Using this proteomic
data, we were able to demonstrate a relationship between protein
expression and genetic variation at the IL28B gene locus, a strong
determinant of treatment-induced HCV clearance. Corticosteroid
binding globulin peptides were strongly associated with IL28B
genotype, accounting for over a third of the variance of the CBG
metaprotein and thus, IL28B may be an important trans-pQTL for
serum CBG levels among HCV-infected individuals. We were
unable to show that CBG mediates the relationship between
IL28B and treatment response, indicating possible pleiotropic
effects of this locus.
CBG, also known as Transcortin, is a major high-affinity plasma
transport protein for glucocorticoids and progestins and is
expressed primarily in the liver. Serum cortisol and CBG levels
are inversely related [15,16], thus, we would expect rs12979860-
CC to associate with not only lower CBG but higher cortisol levels
as well. Cortisol modulates the inflammatory response, and the
primary function of CBG in proinflammatory states such as CHC
infection is to deliver cortisol to sites of inflammation leading to
down regulation of neutrophil activity and the cell mediated
immune system. Treatment of CHC patients with interferon-beta
has been linked to increases in both inflammatory cytokines and
cortisol, but these effects appear to be independent [17]. Similarly,
administration of interferon-alpha has been shown to alter plasma
cortisol levels and immune cytokines, but these appear to be
Table 1. Characteristics of the 41 Chronic HCV patients in the
present study.
Characteristic N (percent)
Race
Caucasian 32 (78%)
African American 9 (22%)
Sex
Male 25 (61%)
Female 16 (39%)
Treatment response
SVR 26 (63%)
NR 15 (37%)
Rs12979860 genotype
CC 20 (49%)
TC 18 (44%)
TT 3 (7%)
Mean 6 SD
Age (years) 47.466.1
doi:10.1371/journal.pone.0021854.t001
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the link between interferon and cortisol levels may hold for
endogenous interferon lambda as well. Moreover, this relationship
is unrelated to treatment response and thus, supports pleiotropic
effects of interferons on the steroid hormone system and treatment
response.
Levels of serum CBG may be altered in chronic disease states,
but are unlikely to confound our results. CBG levels may be
Figure 1. Quantile-Quantile plot showing the distribution of observed P values for IL28B rs12979860 genotype association with 110
metaproteins among chronic HCV patients to the expected distribution of P values under the null hypothesis. The red point denotes
the CBG metaprotein.
doi:10.1371/journal.pone.0021854.g001
Figure 2. Expression level of CBG metaprotein by IL28B rs12979860 genotype in 41 Chronic HCV patients. Filled circles represent non-
responders (NR) to interferon treatment and open circles are from subjects who achieved sustained virologic response (SVR) to treatment.
doi:10.1371/journal.pone.0021854.g002
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however, no patients in this cohort had evidence of impaired
hepatic function or decompensated disease. Moreover, both the
IL28B rs12979860-CC responder genotype and advanced liver
disease areas associated with lower CBG levels, but IL28B
rs12979860-CC is not associated with a lower rate, but rather a
more rapid rate of hepatic fibrosis in CHC patients [20]. In
addition, in vitro studies have demonstrated an inhibitory effect of
insulin and insulin-like growth factor-1 on CBG mRNA expression
in a human hepatoblastoma derived Hep G2 cell-line [21]. The
inverse correlation between insulin and CBG has also been
observed in small clinical studies [22] and upregulation of CBG
has been proposed as a marker of type 1 diabetes mellitus [23].
The prevalence of insulin resistance is increased among patients
with CHC infection and is associated with reduced virologic
response to IFN-based therapy [24]. We did not specifically assess
insulin resistance in our cohort. However, we found the IL28B
rs12979860-C responder allele (and not the rs12979860-T ‘poor
response’ allele that would be expected to associate with insulin
resistance) to be associated with low serum levels of the CBG
metaprotein.
Despite strong statistical support for the observed association
between IL28B and CBG in our study, the results were based on a
relatively small number of patients and should thus be considered
preliminary. Post-pubertal CBG levels do not vary significantly with
age or gender, and there is minimal diurnal variation, thus reducing
the potential influence of normal physiological variation on our
observations [25]. Moreover, the generalizability of these findings,
including whether this is a mechanism specific to infection with
HCV, or an association with a chronic inflammatory state is
unknown. Replication in larger cohorts will be necessary to validate
and extend these findings. Studies that incorporate direct measures
of cortisol and CBG may provide further validation of the
relationship between IL28B genotype and corticosteroids.
The current study utilized proteomic data generated by LC-MS/
MS and analyzed using novel methods to group peptides into
‘metaprotein’ clusters. Thus, the intact proteins were not measured
directly, but rather, specific groups of peptides representing the
protein were measured. The metaprotein algorithm preferentially,
but not exclusively, groups identified peptides according to their
assigned ‘‘parent’’ protein. In addition, the algorithm permits
exclusion of a peptide from the model if its expression trend does
not track with the other peptides, and inclusion of peptides from
different proteins or unidentified peptides which have expression in
common with the metaprotein. In this way, future work correlating
metaproteins with genes identified in pQTL analysis may assist in
identification of currently unidentified proteins, or at least functional
correlation of these unknown peptides with biological mechanisms.
In summary, the current study used an open-proteomic platform
to characterize protein expression associated with a polymorphism
stronglyassociated withHCVclearanceandhaveidentifiedastrong
trans-acting pQTL, providing insight into the biological conse-
quences of this variation. We have found the CBG metaprotein and
its constitutent peptides to be strongly associated with IL28B
genotype, but not mediating the effect of IL28B genotype on
treatment response. Our research showcases the power of pQTL
analysis for the functional annotation of genetic variants.
Materials and Methods
Patient population and ethics statement
Patient samples were selected from the Duke Hepatology Clinical
Research (DHCR) database and were included in a prior validation
study of proteomic signatures of virologic response to current IFN-
based standard-of-care therapy [11]. The cohort included 41
patients with chronic genotype 1 HCV infection who had serum
samples available prior to treatment, known treatment response,and
DNA available for genetic analysis. All patients provided written
informed consent for genetic testing and all study procedures were
approved by the Duke University Institutional Review Board.
Table 2. Statistical associations.
Dependent Variable Independent Variable
{ Additional Covariates
Odds Ratio (95% CI) for
Independent Variable P-value for Independent Variable
SVR CBG sex, race 2.62 (0.93, 8.64) 0.0148
SVR IL28B sex, race 0.03 (0.001,0.19) 0.0021
SVR IL28B sex, race, CBG 0.05 (0.002, 0.39) 0.0145
Beta estimate
CBG IL28B sex, race 1.16 7.45610
25
{For IL28B as the independent variable of interest, we are testing a recessive model, i.e., CC vs. TT/TC.
doi:10.1371/journal.pone.0021854.t002
Figure 3. CBG metaprotein peptide composition. Each gray bar is
a representation of the labeled protein. Red sections represent
polypeptides from isotope groups that are in the factor and black
sections represent polypeptides from the isotope groups that are
identified in the data set but are not in the factor. Gray represents
sections of the protein that are not identified in the data set. %
Coverage is the percent of identified peptides from that protein that are
in the factor and % Signature is the percent of the factor that comes
from the associated protein.
doi:10.1371/journal.pone.0021854.g003
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The genomic region associated with HCV response in [4]
contains several highly correlated SNPs around the IL28B gene.
We selected the most strongly associated SNP, rs12979860,
located upstream of this gene for genotyping in our cohort using
the 59 nuclease assay with allele specific TaqMan probes [26].
Sample preparation and LC-MS/MS analysis
Sample preparation and LC-MS/MS analyses on these samples
have been described previously [11]. Briefly, serum samples were
immunodepleted using MARS14 columns and then subjected to in-
solutiondigestionwith trypsin.LC-MS/MS analysiswascarried out
on a nanoAcquity liquid chromatograph coupled to a QToF
Premier mass spectrometer (Waters Corporation, Milford, MA).
The Rosetta ElucidatorH v3.3 software package (Rosetta Biosoft-
ware, Rosetta Inpharmatics LLC, Seattle, WA) was used to import
and align all LC-MS raw data files and perform feature
quantitation. Mascot v2.2 (Matrix Sciences, Inc, Boston, MA) and
Proteinlynx Global Server v2.4 (Waters Corporation, Milford, MA)
database search engines were used to make peptide identifications.
Metaprotein construction
Several challenges exist in the analysis of proteomic data
generated by LC-MS/MS. Incorrect peptide identifications,
sharing of peptides among homologs, and post-translationally
modified or processed peptides that may show a biologically
relevant and different expression pattern than the proteotypic
peptides, can all lead to errors in the quantitative analysis of
proteins. In order to correct for these multiple sources of noise, we
utilized our metaprotein factor model which groups peptides based
on co-expression. We restricted our analysis to only those peptides
with protein identifications. Because co-expression across the
biological cohort is a central tenant of this modeling approach,
peptides are not exclusively tied to their parent protein and
therefore individual peptides arising from multiple proteins may
potentially comprise a single metaprotein. Metaprotein nomen-
clature was based on predominance of peptides associated with a
known protein. Complete details of how metaprotein expression
levels are generated as well as mathematical details regarding the
metaprotein factor model are described in Document S1. Protein
identification frequency in samples from the 41 CHC patients is
listed in Table S1.
Association analysis
Each metaprotein was analyzed for association with IL28B
genotype using one-way analysis of variance (ANOVA). IL28B
genotypes (TT, CT, CC) were analyzed assuming an additive
model, controlling for sex and race. Subsequent analysis was
carried out assuming a recessive model for the response allele (C),
comparing CC to CT/TT genotypes, consistent with the effect of
this locus on treatment response. All statistical analyses have been
performed using MATLAB; a commented script (Materials S1)
and workspace (Materials S2) have been included as supporting
information.
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Table 3. Association of component peptides from CBG metaprotein with IL28B genotype.
Peptide Monoisotopic M/Z Peak Centroid Time Charge State Peak Time Score P-value
CBG 740.3704 68.17205,
68.173,
68.17549,
68.17624,
68.19092
2 0.8491636,
0.8916217,
0.9133328,
0.95755863,
0.9581282
1.46610
25
CBG 717.356 58.446613,
58.451298,
58.462116,
58.475937,
58.496063,
58.50195,
58.507416
3 0.91022366,
0.91063344,
0.91442996,
0.918305,
0.93158853,
0.93290806,
0.9367805
1.50610
24
AFAM 553.2891 32.656315,
32.71019
1 0.9143975,
0.9606747
1.74610
24
CBG 538.30505 59.005672,
59.028744
2 0.9508445,
0.9678301
2.42610
24
APOB 461.27652 32.52292,
32.57379
2 0.8160564,
0.96448535
3.40610
25
CBG 432.76743 32.560402,
32.605553
1 0.7805042,
0.9042755
5.17610
25
CBG 864.5479 32.484024,
32.5972
3 0.8152123,
0.9661816
6.36610
24
HEMO 1238.0748 66.4398,
66.45684,
66.46535,
66.47275,
66.47417
2 0.80079937,
0.80459476,
0.8478435,
0.88555866,
0.8909334
7.37610
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